|
**Overview**: Flow Cytometry Kappa Lambda Panel**Introduction**: The Flow Cytometry Kappa Lambda Panel is a diagnostic tool designed to assess light chain expression using whole blood samples. In India, kappa/lambda ratio abnormalities are key in B-cell lymphoproliferative disorders (multiple myeloma, CLL, lymphomas) and plasma cell dyscrasias, with clonal restriction (skewed ratio) present in ~90 percent of cases, aiding diagnosis and monitoring. High morbidity from under-testing in rural/low-SES patients with unexplained anemia, renal failure, or bone pain, limited flow cytometry labs, delayed targeted therapy (bortezomib, daratumumab) leading to progression or end-organ damage. Per hematology/immunology practices aligned with ICMR and Indian Society of Hematology guidelines, the test employs flow cytometry for kappa and lambda light chain expression over 1-2 days with high accuracy, valuable for detecting clonality in suspected plasma cell/B-cell malignancies. This diagnostic falls under immune profiling and targets patients with suspected lymphoproliferative disorders, addressing accurate detection to guide biopsy, therapy, and monitoring. With elevated morbidity due to under-testing, the test supports public health efforts by enabling precise immunophenotyping and improving outcomes. Its whole blood-based approach ensures reliable light chain analysis.**Other Names**: Flow Kappa Pnl.**FDA Status**: FDA approved, CLIA certified for hematology/immunology, compliant with 2025 standards.**Historical Milestone**: Kappa/lambda flow standard; in India, used in myeloma/CLL protocols.**Purpose**: The test assesses 2 parameters including kappa light chain to guide light chain expression evaluation, detect clonality, inform management.**Test Parameters**: 1. Kappa Light Chain, 2. Lambda Light Chain.**Pretest Condition**: No fasting required; patients should have suspected B-cell/plasma cell disorder.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve cell viability, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for flow).**Medical History**: Patients should provide details on anemia, renal issues, bone pain, prior therapy.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed clonality including progression, benefits of profiling, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using flow cytometry by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low lymphocyte count can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Skewed kappa/lambda ratio indicates clonality, necessitating specialist input. Normal ratio may require follow-up if suspicion high.**Specialist Consultation**: Hematologists should be consulted for management.**Additional Supporting Tests**: Serum free light chains, bone marrow biopsy for confirmation.**Test Limitations**: Requires viable cells; comprehensive approach required.**References**: Indian Journal of Hematology 2024, Flow Studies India 2023. |
